Micogel
Formulated to alleviate dermal fungal infections to support skin barrier restoration and target cell membrane synthesis.
- Categories
- Antifungals · Skin Care
- Active ingredient
- Miconazole
- Route
- Cutaneous use
- Form
- Tablet
- Strengths
- 2%
Prescription and consultation requirements for Micogel vary by destination and are determined by the fulfilment partner.
Micogel details
- Conditions
- Tinea Pedis · Tinea Cruris · Tinea Corporis · Cutaneous Candidiasis
- Alternative names
- miconazole
- Therapeutic class
- Imidazole Antifungal
- Pharmacological class
- Topical Antifungal
- Contraindications
- hypersensitivity to miconazole
- Minor side effects
- local skin irritation; burning sensation
- Moderate side effects
- erythema; dry skin; pruritus
- Serious side effects
- severe local contact dermatitis, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Cutaneous use
- Supply category
- Pharmacy medicine (P), available from a pharmacist without a prescription
- Manufacturer
- Cipla Ltd
- Onset Time
- 1–2 weeks
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Warfarin
- Age restrictions
- Approved for infants, children, and adults.
Patient summary
formulated to alleviate dermal fungal infections to support skin barrier restoration and target cell membrane synthesis.
Mechanism of action
Blocks lanosterol demethylation inside fungi, disrupting membrane ergosterol synthesis to clear superficial pathogens.
Pregnancy and breastfeeding
TGA Category C: Safe for localised topical use. Breastfeeding: Do not apply to breasts.